Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.
Chemical inhibition of chromatin-mediated signaling involved proteins is an established strategy to drive expression networks and alter disease progression. Protein methyltransferases are among the most studied proteins in epigenetics and, in particular, disruptor of telomeric silencing 1-like (DOT1L) lysine methyltransferase plays a key role in MLL-rearranged acute leukemia Selective inhibition of DOT1L is an established attractive strategy to breakdown aberrant H3K79 methylation and thus overexpression of leukemia genes, and leukemogenesis. Although numerous DOT1L inhibitors have been several structural data published no pronounced computational efforts have been yet reported. In these studies a first tentative of multi-stage and LB/SB combined approach is reported in order to maximize the use of available data. Using co-crystallized ligand/DOT1L complexes, predictive 3-D QSAR and COMBINE models were built through a python implementation of previously reported methodologies. The models, validated by either modeled or experimental external test sets, proved to have good predictive abilities. The application of these models to an internal library led to the selection of two unreported compounds that were found able to inhibit DOT1L at micromolar level. To the best of our knowledge this is the first report of quantitative LB and SB DOT1L inhibitors models and their application to disclose new potential epigenetic modulators.
['Sabatino|Manuela|M|', 'Rotili|Dante|D|', 'Patsilinakos|Alexandros|A|', 'Forgione|Mariantonietta|M|', 'Tomaselli|Daniela|D|', 'Alby|Fréderic|F|', 'Arimondo|Paola B|PB|', 'Mai|Antonello|A|', 'Ragno|Rino|R|0000-0001-5399-975X']
D015195:Drug Design D004791:Enzyme Inhibitors D008024:Ligands D008780:Methyltransferases D008958:Models, Molecular D011485:Protein Binding D011487:Protein Conformation D021281:Quantitative Structure-Activity Relationship
Disruptor of telomeric silencing 1-like (DOT1L) COMBINE 3-D QSAR Ligand-Based Drug Design Structure-Based Drug Design